<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03751007</url>
  </required_header>
  <id_info>
    <org_study_id>AG019-T1D-101</org_study_id>
    <secondary_id>2017-002871-24</secondary_id>
    <nct_id>NCT03751007</nct_id>
  </id_info>
  <brief_title>A Study to Assess the Safety and Tolerability of Different Doses of AG019 Administered Alone or in Combination With Teplizumab in Participants With Recently Diagnosed Type 1 Diabetes Mellitus (T1D)</brief_title>
  <official_title>A Prospective, Multi-center, Phase 1b/2a Study to Assess the Safety and Tolerability of Different Doses of AG019 Administered Alone or in Association With Teplizumab in Patients With Clinical Recent-onset Type 1 Diabetes Mellitus (T1D)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Precigen Actobio T1D, LLC</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Intrexon Actobiotics NV, d/b/a Precigen Actobio</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>TFS Trial Form Support</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Precigen Actobio T1D, LLC</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to assess the safety and tolerability of different doses of
      AG019 administered alone or in combination with teplizumab in participants who recently
      developed Type 1 Diabetes Mellitus (T1D).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This Phase 1b/2a, multi-center study will be conducted in participants with clinical
      recent-onset Type 1 Diabetes Mellitus (T1D).

      The primary objective of this study is to assess the safety and tolerability of different
      doses of AG019 alone as well as AG019 in association with teplizumab. The secondary
      objectives of this study are: to obtain pharmacodynamic (PD) data of AG019 alone as well as
      AG019 in association with teplizumab; and to determine the potential presence of AG019 in
      systemic circulation (safety - systemic exposure) and the presence of L. lactis bacteria in
      fecal excretion (local exposure): Pharmacokinetic (PK) profile.

      This study consists of 2 phases:

      Phase 1b: this open-label part of the study will investigate the safety and tolerability of 2
      different doses of AG019 in 2 age groups (18-40 years of age and 12-17 years of age).

      Phase 2a: this randomized, double-blind part of the study will investigate the safety and
      tolerability of AG019, in association with teplizumab, in 2 age groups (18-40 years of age
      and 12-17 years of age).
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">October 27, 2018</start_date>
  <completion_date type="Anticipated">May 30, 2021</completion_date>
  <primary_completion_date type="Anticipated">October 31, 2020</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <intervention_model_description>The Phase 1b part of the study will enroll 4 sequential AG019 cohorts of up to 6 Participants, in ascending dose cohorts and descending age cohorts. All participants in these cohorts will be treated with AG019 in an open label fashion.
The Phase 2a part of the study will evaluate 2 cohorts of participants administered AG019 and teplizumab. The first 2 participants will be treated with active treatment in an open label fashion. Participants 3-12 will be randomized (4:1) to receive active treatment or placebo in a double-blind fashion.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
    <masking_description>For the randomized participants in the combination cohorts, blinding will be accomplished by arranging for AG019 and placebo components as well as teplizumab and placebo components to have identical packaging.</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Number of participants with treatment-related adverse events assessed by the investigator, review of lab reports and information provided by the participant during site visits and/or participant diary during treatment with AG019 alone or with teplizumab</measure>
    <time_frame>up to 6 months from screening</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Immune marker cell count in systemic circulation.</measure>
    <time_frame>Up to 12 months after initiation of the treatment</time_frame>
    <description>Immune markers will be measured in cells/mm^3 and may include: human proinsulin (hPINS), specific cluster of differentiation(CD)4+ T cells and circulating interleukin-10 (IL-10) producing CD4+ T cells</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cytokines/chemokines in systemic circulation.</measure>
    <time_frame>Up to 12 months after initiation of the treatment</time_frame>
    <description>Cytokines/chemokines will be measured in pg/mL and may include: interferon(IFN)-gamma, IL-10 and chemokine receptor type 6 (CCR6)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AG019 in systemic circulation</measure>
    <time_frame>Up to 12 months after initiation of the treatment</time_frame>
    <description>The presence of live L. Lactis bacteria in blood will be assessed by plating</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>L. Lactis-secreted hPINS or hIL-10 in systemic circulation</measure>
    <time_frame>Up to 12 months after initiation of the treatment</time_frame>
    <description>The presence of L. lactis-secreted hPINS or hIL-10 in the blood will be assessed by ELISA (enzyme-linked immunosorbent assay)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AG019 in feces</measure>
    <time_frame>Up to 12 months after initiation of the treatment</time_frame>
    <description>The presence of L. lactis (live or dead) in feces will be assessed by Q-PCR (quantitative real-time polymerase chain reaction)</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Number of participants with treatment-emergent adverse events as assessed by the investigator observed at timepoints other than those specified in the Primary Outcome.</measure>
    <time_frame>Up to 12 months from screening</time_frame>
  </other_outcome>
  <number_of_arms>6</number_of_arms>
  <enrollment type="Anticipated">48</enrollment>
  <condition>Diabetes Mellitus, Type 1</condition>
  <arm_group>
    <arm_group_label>AG019 Cohort 1 - Low Dose/Adults</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>AG019 Cohort 2 - High Dose/Adults</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>AG019 Cohort 3 - Low Dose/Adolescents</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>AG019 Cohort 4 - High Dose/Adolescents</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Combination Cohort 1 - Adults</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Combination Cohort 2 - Adolescents</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>AG019 - Low Dose</intervention_name>
    <description>Solid, orally administered capsule - 2 capsules per day for 1 day (single dose) or 8 weeks (repeat dose)</description>
    <arm_group_label>AG019 Cohort 1 - Low Dose/Adults</arm_group_label>
    <arm_group_label>AG019 Cohort 3 - Low Dose/Adolescents</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Teplizumab</intervention_name>
    <description>Daily IV infusions of Teplizumab during the first 12 days of AG019 treatment. Total cumulative dose is approximately 17mg (dose calculation based on body surface area).</description>
    <arm_group_label>Combination Cohort 1 - Adults</arm_group_label>
    <arm_group_label>Combination Cohort 2 - Adolescents</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo-AG019</intervention_name>
    <description>Formulated identically to AG019 with the active ingredient removed.</description>
    <arm_group_label>Combination Cohort 1 - Adults</arm_group_label>
    <arm_group_label>Combination Cohort 2 - Adolescents</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo-Teplizumab</intervention_name>
    <description>Formulated identically to teplizumab with the active ingredient removed.</description>
    <arm_group_label>Combination Cohort 1 - Adults</arm_group_label>
    <arm_group_label>Combination Cohort 2 - Adolescents</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>AG019 - High Dose</intervention_name>
    <description>Solid, orally administered capsule - 6 capsules per day for 1 day (single dose) or 8 weeks (repeat dose)</description>
    <arm_group_label>AG019 Cohort 2 - High Dose/Adults</arm_group_label>
    <arm_group_label>AG019 Cohort 4 - High Dose/Adolescents</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>AG019 - Low or High Dose</intervention_name>
    <description>Solid, orally administered capsule - 2 or 6 capsules per day for 8 weeks (repeat dose).</description>
    <arm_group_label>Combination Cohort 1 - Adults</arm_group_label>
    <arm_group_label>Combination Cohort 2 - Adolescents</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male or non-pregnant, non-lactating females, 18 - 40 years of age (both inclusive) or
             12-17 years of age (both inclusive)

          -  Diagnosis of diabetes according to the American Diabetes Association (ADA) recommended
             criteria

          -  Evidence of auto-antibodies to at least 1 β-cell autoantigen

          -  Stimulated C-peptide measured during 4h Mixed Meal tolerance Test (MMTT) &gt; 0.2 nmol/L

          -  The first administration of AG019 should occur no later than 150 days post diagnosis
             of diabetes

          -  Body weight ≥ 33kg

          -  Written informed consent obtained and documented (participant, parent, guardian as
             applicable)

        Exclusion Criteria:

          -  Previous history of serious cytokine release syndrome to teplizumab or other humanized
             anti-CD3 monoclonal antibodies with no or minimal capacity to bind Fc receptors.
             (Participants enrolled in the second phase of the trial in either Combination Cohort 1
             or Combination Cohort 2, only)

          -  Use of immunosuppressive or immunomodulatory therapies, including systemic steroids
             within 1 month prior to randomization

          -  Participation in another investigational drug trial within 12 weeks prior to the first
             study drug intake and during participation in this study

          -  History of recurrent infections, other autoimmune diseases, cardiac disease,
             malignancy, or any other (chronic) medical condition which, in the investigator's
             opinion, could compromise participant safety

          -  Documented history of human immunodeficiency virus (HIV), Hepatitis Virus Type C
             (HCV), Hepatitis Virus Type B (HBV) infection

          -  Evidence of active infection with Epstein-Barr Virus (EBV) or cytomegalovirus (CMV)

          -  Evidence of active or latent tuberculosis (TB)

          -  Administration of anti-CD3 antibody in past year

          -  Current therapy with any other anti-diabetic agents other than insulin (MDI, CSII or
             analogue). Current or planned therapy with experimental (i.e., unapproved) insulin.
             Patients on therapy for type 2 diabetes (e.g. metformin) should stop their therapy in
             order to be eligible for study participation.

          -  Use of medications known to influence glucose tolerance

          -  Daily use of non-steroidal anti-inflammatory agents

          -  Compromised GI mucosal integrity or motility, not attributable to T1D (i.e., recent
             diarrhea, gluten sensitive enteropathy, inflammatory bowel disease, irritable bowel
             syndrome), or current use of medications known to influence GI motility

          -  Positive result of SARS-Cov2 PCR test at screening or within 3 days before
             randomization
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>12 Years</minimum_age>
    <maximum_age>40 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Chantal Mathieu, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Hospital of Leuven, Clinical and Experimental Endocrinology</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Kevan Herold, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Yale Center for Clinical Investigation; Yale University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Sven Blomme</last_name>
    <phone>+32 9 277 11 77</phone>
    <email>sblomme@actobio.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Joan Vermeiren</last_name>
    <phone>+32 (0)476 43 12 95</phone>
    <email>JVermeiren@actobio.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>University of Alabama, Birmingham</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>35294</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>University of California, San Francisco</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94158</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Christine Torok, RN</last_name>
      <phone>415-502-9089</phone>
      <email>christine.torok@ucsf.edu</email>
    </contact>
    <investigator>
      <last_name>Steve Gitelman, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Coastal Metabolic Research Centre</name>
      <address>
        <city>Ventura</city>
        <state>California</state>
        <zip>93003</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Ronald H Chochinov, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Colorado</name>
      <address>
        <city>Aurora</city>
        <state>Colorado</state>
        <zip>80045</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Hali Broncucia</last_name>
      <phone>303-724-7526</phone>
      <email>hali.broncucia@ucdenver.edu</email>
    </contact>
    <investigator>
      <last_name>Peter Gottlieb, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Yale Center for Clinical Investigation</name>
      <address>
        <city>New Haven</city>
        <state>Connecticut</state>
        <zip>06519</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Linda Ryall</last_name>
      <phone>203-737-4510</phone>
      <email>linda.ryall@yale.edu</email>
    </contact>
    <investigator>
      <last_name>Kevan Herold, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Miami</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33136</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Della Matheson, RN, CDE</last_name>
      <phone>305-243-3781</phone>
      <email>dmatheso@med.miami.edu</email>
    </contact>
    <investigator>
      <last_name>David Baidal, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of South Florida</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <zip>33612</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Emily Eyth</last_name>
      <phone>813-974-2793</phone>
      <email>emilyeyth@health.usf.edu</email>
    </contact>
    <investigator>
      <last_name>Henry Rodriguez, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Barry J Reiner, MD, LLC</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21229</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ranessa Labovitz</last_name>
      <phone>410-646-4009</phone>
      <email>bjrstudy@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Barry J Reiner, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Minnesota Health</name>
      <address>
        <city>Minneapolis</city>
        <state>Minnesota</state>
        <zip>55454</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>University of Missouri-Kansas City School of Medicine</name>
      <address>
        <city>Kansas City</city>
        <state>Missouri</state>
        <zip>64108</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jennifer Bedard</last_name>
      <phone>816-960-8940</phone>
      <email>jabedard@cmh.edu</email>
    </contact>
    <investigator>
      <last_name>Wayne Moore, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Sanford Children's Specialty Clinic</name>
      <address>
        <city>Sioux Falls</city>
        <state>South Dakota</state>
        <zip>57117</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lacey DeGeest</last_name>
      <phone>605-328-1368</phone>
      <email>DiabetesResearch@sanfordhealth.org</email>
    </contact>
    <investigator>
      <last_name>Kurt Griffin, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University Diabetes and Endocrine Consultants</name>
      <address>
        <city>Chattanooga</city>
        <state>Tennessee</state>
        <zip>37411</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Texas Diabetes &amp; Endocrinology, P.A.</name>
      <address>
        <city>Austin</city>
        <state>Texas</state>
        <zip>78749</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Tira Chaicha-Brom, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Research Institute of Dallas</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75231</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Stephen Louis Aronoff</last_name>
      <phone>214-265-2137</phone>
      <email>research@researchdallas.com</email>
    </contact>
    <investigator>
      <last_name>Stephen Louis Aronoff, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Benaroya Research Institute</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98101</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Marli McCulloch-Olson</last_name>
      <phone>206-342-6943</phone>
      <email>marli@benaroyaresearch.org</email>
    </contact>
    <investigator>
      <last_name>Carla Greenbaum, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>UZ Brussel</name>
      <address>
        <city>Brussels</city>
        <zip>1090</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Valérie Van Damme</last_name>
      <phone>+32 2 477 77 60</phone>
      <email>valerie.vandamme@uzbrussel.be</email>
    </contact>
    <investigator>
      <last_name>Bart Keymeulen, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>UZ Antwerpen</name>
      <address>
        <city>Edegem</city>
        <zip>2650</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Rie Braspenning</last_name>
      <phone>+3238214002</phone>
      <email>rie.braspenning@uza.be</email>
    </contact>
    <investigator>
      <last_name>Christophe de Block, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>UZ Leuven</name>
      <address>
        <city>Leuven</city>
        <zip>3000</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Morobe Hilde</last_name>
      <phone>+3216340748</phone>
      <email>hilde.morobe@uzleuven.be</email>
    </contact>
    <investigator>
      <last_name>Chantal Mathieu, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Belgium</country>
    <country>United States</country>
  </location_countries>
  <verification_date>June 2020</verification_date>
  <study_first_submitted>November 8, 2018</study_first_submitted>
  <study_first_submitted_qc>November 20, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">November 23, 2018</study_first_posted>
  <last_update_submitted>June 22, 2020</last_update_submitted>
  <last_update_submitted_qc>June 22, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">June 24, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 1</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

